Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1923P - Assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer in real-life practice in Russia

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Thyroid Cancer

Presenters

Ekaterina Borodavina

Citation

Annals of Oncology (2020) 31 (suppl_4): S1026-S1033. 10.1016/annonc/annonc293

Authors

E. Borodavina, P. Isaev, A. Shurinov, V. Krylov

Author affiliations

  • Radionuclide Therapy Department, A. Tsyb Medical Radiological Research Center, 249036 - Obninsk/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1923P

Background

Although differentiated thyroid cancer (DTC) patients (pts) have a good prognosis; 5-10% of pts become radioiodine-refractory (RR) and experience recurrence or distant metastasis. LEN was approved to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. We assessed the efficacy and safety of LEN in real-life practice in pts with metastatic RR DTC consecutively treated at a single center in Russia.

Methods

Retrospective analysis of 44 pts treated with LEN >2 months from Dec 2015 to Mar 2020 according to the prescribing information of LEN and local standards of treatment. The response was determined by RECIST 1.1, adverse events were assessed using pts and clinical records.

Results

The histological types were papillary DTC (81.8%) and follicular DTC (18.2%). Median age was 65 (range 31-79) years, pts had ECOG status 0-1 (79.5%) and ECOG 2 (20.5%), and 30 (68.2%) pts had 2 or more sites of metastasis. Distant metastases were in lungs, bones, and lymph nodes (95.5%, 20.5%, and 59.1%, respectively). LEN was used as first-line therapy in 34 (77.3%) pts and as second-line after sorafenib in 10 (22.7%) pts. Median duration of treatment was 16 months (range 2-35). By the cut-off day therapy was continued in 35 (79.5%). Complete response, partial response and stable disease were observed in 1 (2.3%), 26 (59.1%) and 9 (20.5%) pts, respectively; progression (PD) was recorded in 2 (4.5%) pts and 6 (13.6%) pts were not evaluable. The most common AEs of any grade in the LEN group were generalized weakness without activity of daily living estimation (90.9%), appetite loss (75.0%), hypertension (68.2%), weight loss (65.9%), diarrhea (50.0%), nausea (31.8%), proteinuria (27.3%), stomatitis (11.4%). Nine (20.5%) pts required treatment discontinuation and reasons were due to death, PD and AE in 5 (11.4%), 2 (4.5%) and 2 (4.5%) pts, respectively. Five deaths occurred. Dose reductions to 20, 18, 14 and 10 mg were in 10 (22.7%), 3 (6.7%), 7 (15.9%) and 7 (15.9%) pts, respectively; 16 (36.4%) pts did not require dose reduction.

Conclusions

61,4 % ORR shows good efficacy of lenvatinib in population of pts with poor performance status (ECOG 1-2).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Eisai LLC Russia.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.